|
⚲
|
| Keyboard |
| Soleus Private Equity Fund I LP
✚
|
|
|---|---|
| CIK # | 0001752427 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001752427] | |
| 4 | [0001752427] | |
| D | [0001752427] | |
| SC 13D | [0001752427] | |
| SC 13G | [0001752427] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Soleus Private Equity Fund I LP | Neuropace Inc | [2021-11-01] |
| Soleus Private Equity Fund I LP | Bioatla Inc | [2020-12-28] |
| Soleus Private Equity Fund I LP | Galecto Inc | [2020-11-12] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Sell | 16,909 | $16.00 | 270,544 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Buy | 155,000 | $16.00 | 2,480,000 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Conversion | 338,330 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Conversion | 104,608 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Option exercise | 31,382 | $8.63 | 270,827 |
|
Lyra Therapeutics Inc LYRA
Series B Convertible Preferred Stock · derivative
|
2020-05-05 | Conversion | 11,666,666 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock Warrant · derivative
|
2020-05-05 | Option exercise | 31,382 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Series C Convertible Preferred Stock · derivative
|
2020-05-05 | Conversion | 3,607,224 | $0.00 |